Analyst Price Targets — TCNNF
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 2, 2022 6:30 am | — | Wedbush | $18.00 | $13.80 | Benzinga | Wedbush Initiates Coverage On Trulieve Cannabis with Outperform Rating, Announces Price Target of $18 |
| November 23, 2021 12:00 am | Owen Bennett | Jefferies | $48.54 | $28.54 | Investing | Jefferies Stick to Their Buy Rating for Trulieve Cannabis |
| May 14, 2021 12:00 am | Scott Fortune | Roth Capital | $57.29 | $39.35 | StreetInsider | Trulieve Cannabis Corp (TRUL:CN) (TCNNF) PT Raised to Cdn$72 at Roth Capital |
| April 15, 2021 12:00 am | Vivien Azer | Cowen & Co. | $65.00 | $39.85 | TheFly | Trulieve Cannabis initiated with an Outperform at Cowen |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for TCNNF

With the continued growth and expansion of the cannabis industry, companies are witnessing another shift. Between the USA and Canada, more companies are focused on better branding and marketing attached to better quality products. Right now, in legal cannabis, it is the battle of genetics and who has what and who is inside their legal facilities. As cannabis becomes more mainstream, consumers, like anything else,…

Trulieve Cannabis Corp. (NYSE:TRLV) rang in a new era for the U.S. cannabis industry on Wednesday, becoming the first American marijuana company to list on a major U.S. stock exchange.

The cannabis sector continues evolving as operators focus on profitability, cash flow, and market expansion. Federal cannabis reform discussions remain a major catalyst. Meanwhile, leading multistate operators continue strengthening their positions across key U.S. markets. Investors searching for cannabis exposure may want to focus on companies with strong retail footprints and improving financial performance.

TALLAHASSEE, Fla., June 9, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that its Board of Directors authorized a share repurchase program pursuant to which the Company may repurchase up to the lesser of (i) $50 million in aggregate value, and (ii) 8,495,038 subordinate voting…

Green Thumb Industries and Tilray are in a strong position to benefit from the reclassification of cannabis as a Schedule III drug. Tilray is well positioned to expand its U.S. operations.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TCNNF.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
